Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor
NCT00352534Phase 3Completed
- Sponsor
- Children's Oncology Group
- Start
- Nov 2006
- Primary completion
- Dec 2014
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Targeted Liposomes
- Countries
- 7
01
Overview
Phase 3, open-label trial of vincristine sulfate liposome injection, actinomycin D and pegylated liposomal doxorubicin in Wilms' tumor (3 arms), sponsored by Children's Oncology Group. Primary endpoints: Event Free Survival Probability at 4 years and Overall Survival Probability at 4 years. Started Nov 2006; status: completed.
02
Drugs
vincristine sulfate liposome injectionactinomycin Dpegylated liposomal doxorubicin
03
Conditions
Wilms' tumor
Beyond the preview
Go deeper on NCT00352534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00352534.